🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Ankara
Clinical trial register · Turkey

Clinical Trials in Ankara, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Turkey and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5432 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:51 UTC
5432
Studies in scope
all four open statuses
2496
Recruiting now
open to new participants
552
Lead sponsors
across recruiting studies
Top sites
Istanbul 2009 Ankara 1457 Izmir 568 Adana 378 Antalya 259
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Hacettepe University132 AstraZeneca102 Merck Sharp & Dohme LLC91 Ankara City Hospital Bilkent73 Ankara Etlik City Hospital64
Site location
Istanbul2009 Ankara1457 Izmir568 Adana378 Antalya259
All 319 locations
Target enrolment
to

Trials with a site in Ankara

1457 of 5432 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Turkey
Start
Recruiting
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
NCT06136624Prostate Cancer Metastatic
DrugsFludrocortisone acetate·Opevesostat·Zytiga·Hydrocortisone
Merck Sharp & Dohme LLC
Phase 3
1,310
Adana, Ankara, Istanbul, Samsun
2023-12-31
Active, closed
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
NCT06079879Essential Thrombocythemia
DrugsAnagrelide·Bomedemstat·Busulfan·Ruxolitinib
Merck Sharp & Dohme LLC
Phase 3
340
Bornova, Ankara, Antalya, Edirne, Istanbul, Kocaeli, Mersin, Samsun
2023-12-31
Recruiting
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
NCT06090539Relapsed/Refractory Non-Hodgkin Lymphoma
DrugsGolcadomide·Mosunetuzumab·Epcoritamab·Rituximab
Bristol-Myers Squibb
Phase 1/2
460
Ankara, Istanbul
2023-12-29
Recruiting
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
NCT06149286Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)
DrugsOdronextamab·Lenalidomide·Rituximab
Regeneron Pharmaceuticals
Phase 3
580
Mamak, Yenimahalle, Ankara, Mezitli, Tekirdağ, Istanbul, Izmir, Sakarya
2023-12-28
Recruiting
A Study to Investigate Efficacy and Safety of Pegtibatinase Compared With Placebo in Participants ≥12 to ≤65 Years of Age With Classical Homocystinuria (HCU) Due to Cystathionine Beta Synthase Deficiency Receiving Standard of Care Treatment
NCT06247085Homocystinuria
DrugPegtibatinase
Travere Therapeutics, Inc.
Phase 3
70
Ankara, Bornova, Istanbul
2023-12-28
Active, closed
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
NCT06141486Multiple Sclerosis
DrugFrexalimab
Sanofi
Phase 3
943
Ankara, Bursa, Eskişehir, Istanbul, Izmir, İzmit, Kayseri, Konya
2023-12-27
Recruiting
Pulmonary Determinants of Cardiorespiratory Fitness in Fontan Patients
NCT05684562Fontan Procedure, Congenital Heart Disease
Hacettepe University
Observational
78
Ankara
2023-12-26
Active, closed
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)
NCT06099782Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma
Drugs) Berahyaluronidase alfa·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 2
147
Adana, Ankara, Izmir
2023-12-26
Active, closed
A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
NCT06140836Carcinoma, Non-Small-Cell Lung
DrugsRepotrectinib·Crizotinib
Bristol-Myers Squibb
Phase 3
190
Yenimahalle, Adana, Ankara, Istanbul, Sakarya
2023-12-21
Recruiting
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06119581Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
DrugsOlomorasib·Pemetrexed·Cisplatin·Carboplatin
Eli Lilly and Company
Phase 3
1,264
Adana, Ankara, Antalya, Bursa, Diyarbakır, Istanbul, Izmir, Kocaeli
2023-12-21
Recruiting
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
NCT06136650Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
DrugsFludrocortisone acetate·Opevesostat·Prednisone Acetate·Hydrocortisone
Merck Sharp & Dohme LLC
Phase 3
1,314
Adana, Ankara, Istanbul, Izmir, Samsun
2023-12-18
Active, closed
REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)
NCT05973773Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
DrugZipalertinib
Taiho Oncology, Inc.
Phase 3
285
Adana, Ankara, Edirne, Etlik, Istanbul, Çankaya
2023-12-18
Recruiting
Cognitive Exercise Therapy Approach Biopsychosocial Questionnaire (BETY-BQ) in Patient with Temporomandibular Disorders
NCT06186830Temporomandibular Disorder, Temporomandibular Joint Disorders, Temporomandibular Joint Dysfunction Syndrome
Hacettepe University
Observational
150
Karabük, Ankara
2023-12-17
Recruiting
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
NCT06170788Non-small Cell Lung Cancer (NSCLC)
DrugsSacituzumab tirumotecan·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
614
Stanbul, Bornova, Talas, Adana, Ankara, Denizli, Istanbul, Samsun
2023-12-15
Recruiting
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
NCT06129864Locally Advanced Head and Neck Squamous Cell Carcinoma
DrugVolrustomig
AstraZeneca
Phase 3
1,145
Ankara, Antalya, Cordaleo, Eskişehir, Istanbul, Yenimahalle
2023-12-14
Recruiting
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
NCT06091865Diffuse Large B-cell Lymphoma (DLBCL)
DrugsOdronextamab·Prednisone/Prednisolone·Vincristine·Doxorubicin
Regeneron Pharmaceuticals
Phase 3
904
Yenimahalle, Mezitli, Tekirdağ, Ankara, Istanbul, Izmir, Sakarya, Samsun
2023-12-13
Recruiting
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
NCT06136559Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsNemtabrutinib·Ibrutinib·Acalabrutinib
Merck Sharp & Dohme LLC
Phase 3
1,200
Ankara, Antalya, Edirne, Istanbul, Izmir, Samsun
2023-12-13
Active, closed
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
NCT06141473Multiple Sclerosis
DrugsCholestyramine·Activated Charcoal·Teriflunomide·Frexalimab
Sanofi
Phase 3
1,655
Ankara, Bursa, Eskişehir, Istanbul, Izmir, İzmit, Kayseri, Konya
2023-12-13
Recruiting
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
NCT06091254Follicular Lymphoma (FL)
DrugsOdronextamab·Prednisone/Prednisolone·Cytoxan·Adriamycin
Regeneron Pharmaceuticals
Phase 3
822
Mamak, Yenimahalle, Ankara, Mezitli, Tekirdağ, Istanbul, Izmir, Kayseri
2023-12-12
Active, closed
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
NCT06065748Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
DrugsGiredestrant·Ribociclib·Abemaciclib·Palbociclib
Hoffmann-La Roche
Phase 3
1,050
Adapazarı, Ankara, Bakirkoy / Istanbul, Izmir, Kadiköy, Mersin, Samsun, Sihhiye/Ankara
2023-12-11
Recruiting
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
NCT05995353Crohn's Disease
DrugRisankizumab
AbbVie
Phase 3
110
Ankara, Istanbul, Kocaeli
2023-12-11
Active, closed
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
NCT06077760Non-small Cell Lung Cancer
DrugsIntismeran autogene·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
868
Stanbul, Bornova, Ankara, Istanbul
2023-12-06
Active, closed
Effects of Social Media Addiction on Physical Activity Level and Exercise Capacity in University Students
NCT06187766Addiction, Social Media Addiction, Physical Inactivity
Gazi University
Observational
110
Ankara
2023-12-05
Active, closed
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
NCT06109779Biliary Tract Cancer
DrugsGemcitabine/Cisplatin·Rilvegostomig·Tegafur·Capecitabine
AstraZeneca
Phase 3
760
Ankara, Antalya, Erzurum, Fatih-Istanbul, Samsun
2023-12-04
Recruiting
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
NCT06103864Breast Cancer
DrugsDatopotamab deruxtecan·Durvalumab·Nab-paclitaxel·Gemcitabine
AstraZeneca
Phase 3
625
Ankara, Besevler Ankara, Istanbul, Izmir, Küçükçekmece, Samsun
2023-11-23
Recruiting
Anterior Cruciate Ligament Reconstruction With a Periosteal - Patellar Tendon - Bone Autograft - The Kocabey Press-Fit Technique
NCT06190223Anterior Cruciate Ligament Rupture
Ankara City Hospital Bilkent
Observational
150
Ankara
2023-11-23
Active, closed
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
NCT06120491Metastatic Castration-Sensitive Prostate Cancer
DrugsSaruparib·Zytiga·Xtandi·Abiraterone acetate
AstraZeneca
Phase 3
1,898
Ankara, Bornova-Izmir, Cordaleo, Fatih-Istanbul, Istanbul
2023-11-21
Recruiting
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
NCT05920356Non-Small Cell Lung Cancer (NSCLC)
DrugsSotorasib·Pembrolizumab
Amgen
Phase 3
750
Adana, Ankara, Antalya, Aydin, Denizli, Istanbul, Izmir, Samsun
2023-11-16
By invitation
A New Dual Task Test Method for Football Players
NCT05218993Sports Physical Therapy, Multi-Tasking Behavior, ACL Injury, Kinesiophobia
Hacettepe University
Observational
60
Ankara
2023-11-15
Recruiting
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
NCT06095583Limited-stage Small Cell Lung Cancer (LS-SCLC)
DrugsTifcemalimab·Toripalimab
Shanghai Junshi Bioscience Co., Ltd.
Phase 3
756
Ankara, Edirne, Istanbul, Izmir, Kocaeli, Konya, Malatya
2023-11-15
Active, closed
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.
NCT06063967Crohn's Disease
DrugsSkyrizi·Risankizumab
AbbVie
Phase 3
289
Yenimahalle, Dilovası, Ankara, Antalya, Izmir, Mersin
2023-11-15
Active, closed
A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202
NCT06062420Neoplasms, Head and Neck
DrugsRemzistotug·Nelistotug·Belrestotug·Dostarlimab
GlaxoSmithKline
Phase 2
316
Ankara, Istanbul, Izmir
2023-11-14
Active, closed
A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma
NCT06097364Follicular Lymphoma (FL)
DrugsOdronextamab·Prednisone/Prednisolone·Cytoxan·Adriamycin
Regeneron Pharmaceuticals
Phase 3
733
Mamak, Yenimahalle, Ankara, Mezitli, Sakarya, Tekirdağ, Istanbul, Kayseri
2023-11-14
Active, closed
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
NCT06112379Breast Cancer
DrugsDatopotamab deruxtecan·Xeloda·Epirubicin·Olaparib
AstraZeneca
Phase 3
1,902
Adapazarı, Ankara, Istanbul, Kayseri, Samsun
2023-11-14
Active, closed
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
NCT06074588Non-small Cell Lung Cancer (NSCLC)
DrugsTaxotere·Sacituzumab tirumotecan·Pemetrexed·Docetaxel
Merck Sharp & Dohme LLC
Phase 3
556
Stanbul, Bornova, Adana, Ankara, Istanbul
2023-11-12
Active, closed
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
NCT06073821CLL
DrugsSonrotoclax·Zanubrutinib·Obinutuzumab·Venetoclax
BeOne Medicines
Phase 3
652
Ankara, Kayseri, Kocaeli
2023-11-11
Recruiting
Effect of Guided Imagery on Chemotherapy-related Nausea and Vomiting
NCT06120764Chemotherapy-induced Nausea and Vomiting, Pediatric Cancer
Baskent University
Not applicable
40
Ankara
2023-11-10
Active, closed
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
NCT06097728Unresectable Pleural Mesothelioma
DrugsVolrustomig·Ipilimumab·Pemetrexed·Nivolumab
AstraZeneca
Phase 3
863
Ankara, Diyarbakır, Izmir
2023-11-09
Active, closed
A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2
NCT06072183Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo
DrugRitlecitinib
Pfizer
Phase 3
1,571
Ankara, Istanbul
2023-11-08
Active, closed
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
NCT05925803Systemic Sclerosis, Scleroderma
AstraZeneca
Phase 3
314
Ankara, Antalya, Center, Kazımkarabekir, Kocaeli
2023-11-08
Active, closed
Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)
NCT06087835Chronic Kidney Disease With High Proteinuria
DrugDapagliflozin
AstraZeneca
Phase 3
1,835
Adapazarı, Ankara, Bursa, Dinar, Kahramanmaraş, Kayseri, Kocaeli
2023-11-07
Active, closed
"ADE Fibrinogen/RBC" Ratio on Mortality and Outcome in Massive Transfusion Patients
NCT06021184Massive Transfusion, Bleeding During/Following Surgery
Ankara City Hospital Bilkent
Observational
1,679
Ankara
2023-11-07
Recruiting
Investıgatıon Of The Effectıveness Of The Mollıı Suıt In Chıldren Wıth Ambulatory Cerebral Palsy
NCT06109129Cerebral Palsy, Spasticity, Muscle
Kastamonu University
Not applicable
32
Ankara
2023-11-05
Active, closed
A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma
NCT06054555Melanoma
DrugsOpdivo·Nivolumab
Amgen
Phase 3
633
Yenimahalle/Ankara, Kadıköy, Adana, Ankara, Bursa, Gaziantep, Istanbul, Izmir
2023-11-02
Recruiting
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
NCT05696626Metastatic Breast Cancer
DrugsAbemaciclib·Fulvestrant
LeonaBio
Phase 3
600
Çankaya, Çapa, Kadiköy, Bornova, Konak, İzmit, Ankara, Bursa
2023-10-31
Active, closed
A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive
NCT05879822Advanced Solid Tumor
DrugINCB099280
Incyte Corporation
Phase 2
73
Adana, Ankara, Edirne, Istanbul, Kocaeli
2023-10-30
Active, closed
A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.
NCT05985915Sjogrens Syndrome
DrugIanalumab
Novartis Pharmaceuticals
Phase 3
612
Ankara, Köseköy
2023-10-27
Recruiting
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
NCT05899608Non-Small Cell Lung Cancer
DrugsIvonescimab·Pembrolizumab
Summit Therapeutics
Phase 3
1,600
Sur, Bornova, İzmit, Meram, Ankara, Gaziantep, Istanbul, Izmir
2023-10-26
Active, closed
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
NCT06052059Ulcerative Colitis
DrugTulisokibart
Merck Sharp & Dohme LLC
Phase 3
1,020
Istanbul- Fatih, Ankara, Antalya, Edirne, Eskişehir, Istanbul, Kocaeli
2023-10-25
Active, closed
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
NCT05984277Metastatic Non-small Cell Lung Cancer
DrugsVolrustomig·Pemetrexed·Paclitaxel·Carboplatin
AstraZeneca
Phase 3
895
Ankara, Antalya, Çankaya, Diyarbakır, Fatih-Istanbul, Istanbul, Izmir, Pamukkale
2023-10-24
Recruiting
Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodeficiency
NCT05879757Multiple Myeloma, Secondary Immunodeficiency (SID)
Takeda
Observational
75
Ankara, Antalya, Istanbul
2023-10-17
Active, closed
A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
NCT06095115Plaque Psoriasis
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 3
684
Ankara, Kayseri, Samsun
2023-10-12
Recruiting
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
NCT06012240Alopecia Areata
DrugUpadacitinib
AbbVie
Phase 3
1,500
Ankara, Gaziantep, Istanbul, Kayseri
2023-10-11
Active, closed
A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma
NCT05888844Cutaneous Squamous Cell Carcinoma
DrugINCB099280
Incyte Corporation
Phase 2
63
Adana, Ankara, Edirne
2023-10-09
Active, closed
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
NCT06008756Arteriosclerosis, Hypercholesterolaemia
DrugsEnlicitide Decanoate·Enlicitide
Merck Sharp & Dohme LLC
Phase 3
14,550
Altindağ, Bornova, Cordaleo, Melikgazi, Adana, Ankara, Antalya, Çanakkale
2023-10-09
Active, closed
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
NCT05952557Breast Cancer, Early Breast Cancer
DrugsCamizestrant·Tamoxifen·Exemestane·Anastrozole
AstraZeneca
Phase 3
5,511
Ankara, Antalya, Bursa, Çiğli, Istanbul, Samsun
2023-10-05
Recruiting
Functional Performance and Biopsychosocial Characteristics in Individuals with Systemic Sclerosis
NCT06594302Systemic Sclerosis (SSc)
Hacettepe University
Observational
50
Ankara
2023-10-04
Recruiting
Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN
NCT05755386IC-MPGN
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
106
Istanbul, Izmir, Köseköy, Kayseri, Ankara, Mersin
2023-10-02
Recruiting
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
NCT05609630Juvenile Idiopathic Arthritis
DrugsUpadacitinib·Tocilizumab
AbbVie
Phase 3
90
Ankara, Istanbul
2023-10-02
Active, closed
Evaluation of 2-year Clinical Performance of Two Different Single Color Universal Composite Resin Restorative Materials.
NCT06125132Tooth Discoloration, Tooth Wear
Baskent University
Not applicable
55
Ankara
2023-10-01
Active, closed
Clinical Results of Arthroscopic-Assisted Lower Trapezius Tendon Transfer for Massive, Irreparable Rotator Cuff Tears
NCT06258278Massive Irreparable Rotator Cuff Tears
Gazi University
Not applicable
25
Ankara
2023-10-01
Recruiting
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
NCT06079671Locally Advanced Cervical Cancer
DrugVolrustomig
AstraZeneca
Phase 3
800
Adana, Ankara, Cordaleo, Istanbul
2023-09-22
By invitation
An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007
NCT06075537Mucopolysaccharidosis II
DrugTividenofusp alfa
Denali Therapeutics Inc.
Phase 2/3
99
Adana, Ankara
2023-09-20
Active, closed
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
NCT06047080Large B-Cell Lymphoma
DrugsPolatuzumab Vedotin·Glofitamab·Doxorubicin·Prednisone
Hoffmann-La Roche
Phase 3
1,130
Ankara, Istanbul, İzmit
2023-09-18
Active, closed
Ankura™ AAA, Cuff and AUI Stent Graft System Post-Market Clinical Follow-Up
NCT05864560Abdominal Aortic Aneurysm
Lifetech Scientific (Shenzhen) Co., Ltd.
Observational
164
Ankara
2023-09-15
Active, closed
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)
NCT05904886Hepatocellular Carcinoma
DrugsTiragolumab·Avastin·Tecentriq·Atezolizumab
Hoffmann-La Roche
Phase 3
687
Adana, Ankara, Edirne, Kar?iyaka
2023-09-14
Active, closed
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
NCT06003426Idiopathic Pulmonary Fibrosis
DrugAdmilparant
Bristol-Myers Squibb
Phase 3
1,255
Gümüşhane, Ankara, Bursa, Izmir, Maltepe, Pasaport, Topkapı
2023-09-14
Active, closed
A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome
NCT05946941Sjögren's Syndrome
DrugDeucravacitinib
Bristol-Myers Squibb
Phase 3
774
Yenimahalle, Ankara, Antalya, Istanbul
2023-09-11
Recruiting
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
NCT05894239Metastatic Breast Cancer
DrugsPhesgo·Inavolisib
Hoffmann-La Roche
Phase 3
230
Adapazarı, Ankara, Bakirkoy / Istanbul, Diyarbakır, Istanbul, Izmir, Seyhan, Sihhiye/Ankara
2023-09-08
Recruiting
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
NCT06051617Primary Biliary Cholangitis
DrugSeladelpar
Gilead Sciences
Phase 3
402
Adana, Ankara, Gaziantep, Görükle, Izmir, Karabağlar, Kocaeli, Mersin
2023-09-07
Recruiting
Rescue of Nephrons With ALE.F02 (RENAL-F02)
NCT06047171Glomerulonephritis Rapidly Progressive
DrugsCyclophosphamid·Rituximab
Alentis Therapeutics AG
Phase 2
80
Ankara, Istanbul, Kocaeli, Melikgazi
2023-09-07
Recruiting
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
NCT06051409Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
DrugOlverembatinib
Ascentage Pharma Group Inc.
Phase 3
350
Ankara, Antalya, Istanbul, Izmir, Kayseri, Mersin, Samsun, Tekirdağ
2023-08-31
Recruiting
Magnetic Stimulation of Diaphragm in Chronic Obstructive Pulmonary Disease
NCT06714721Chronic Obstructive Pulmonary Disease (COPD)
Ankara University
Not applicable
66
Ankara
2023-08-23
Recruiting
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
NCT05947851Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic, Small-Cell Lymphoma, Lymphoma, Small Lymphocytic
DrugsNemtabrutinib·Venetoclax·Rituximab
Merck Sharp & Dohme LLC
Phase 3
735
Bornova, Tekirdağ, Ankara, Istanbul
2023-08-08
Active, closed
A Phase 1/Phase 2 Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Intravenous Administration of SAR444836 in Adult Participants With Phenylketonuria
NCT05972629Phenylketonuria
Sanofi
Phase 1/2
32
Ankara
2023-08-07
Recruiting
Evaluation of the Frequency, Risk Factors, and Outcomes of ROP in Infants With a BW >1500 Grs or GA ≥33 Wks in Turkey.
NCT06265363Retinopathy of Prematurity
Baskent University Ankara Hospital
Observational
1,000
Ankara
2023-08-01
Recruiting
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
NCT05855200Colonic Neoplasms, Neoplasms, Colon
DrugsCapeox·Dostarlimab·Folfox
GlaxoSmithKline
Phase 3
892
Ankara, Istanbul
2023-08-01
Recruiting
This Study Aims to Evaluate the Effect of Rinsing Off or Blot-drying Silver Fluoride on the Retention of Subsequently-applied Resin- and Glass Ionomer-based Fissure Sealants in Permanent Molars Affected by Molar-Incisor Hypomineralization.
NCT06641011Molar Incisor Hypomineralisation, Children, Dental Caries
Hacettepe University
Not applicable
104
Ankara
2023-07-31
Active, closed
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
NCT05933577Melanoma
DrugsIntismeran autogene·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
1,089
Ankara, Istanbul, Izmir
2023-07-19
By invitation
Posture Exercises in Parkinson's Disease
NCT06848257Parkinson
Yuksek Ihtisas Hospital
Not applicable
36
Ankara
2023-07-15
Active, closed
Clinical Performance of Novel Alkasite Restorative Material "Cention Forte" in Class II Restorations
NCT06833528Dental Caries, Dental Caries Class II
Hacettepe University
Not applicable
38
Ankara
2023-07-13
Active, closed
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up
NCT05677451Chronic Spontaneous Urticaria
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
100
Istanbul, Ankara, Adana
2023-07-11
Recruiting
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
NCT05980949Psychosis Associated With Alzheimer's Disease
DrugKarXT
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
1,000
Atakum, Ankara, Eskişehir, Istanbul, Izmir
2023-07-11
Active, closed
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
NCT05671510Non Small Cell Lung Cancer
DrugsGotistobart·Taxotere·Docetaxel
OncoC4, Inc.
Phase 3
630
Adana, Ankara, Antalya, Edirne, Fatih, Istanbul, Izmir
2023-06-28
Active, closed
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
NCT05827016Multiple Myeloma
DrugsIberdomide·Lenalidomide
Bristol-Myers Squibb
Phase 3
1,230
Ankara, Çankaya, Edirne, Istanbul, Izmir, Kayseri, Yenimahalle
2023-06-22
Recruiting
Validity and Reliability of the Virtual Reality-Based 9-Hole Peg Test in Stroke Patients
NCT06583772Stroke
Ankara University
Observational
46
Ankara
2023-06-22
Active, closed
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
NCT05889182Hidradenitis Suppurativa
DrugUpadacitinib
AbbVie
Phase 3
1,328
Ankara, Bayraklı, Bursa, Istanbul, Kayseri, Samsun
2023-06-21
By invitation
Psychoeducation Program for Parents of Children with Duchenne Muscular Dystrophy
NCT06412328Psychoeducation, Parents, Psychological Wellness, Duchenne Muscular Dystrophy
Lokman Hekim University
Not applicable
26
Ankara
2023-06-21
Active, closed
Clinical Performance of Injectable Composite Resins in Class I Cavities
NCT06192667Caries,Dental
Hacettepe University
Not applicable
30
Ankara
2023-06-12
Recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
NCT05646862Breast Cancer
DrugsBupropion·Omeprazole·Alpelisib·Inavolisib
Hoffmann-La Roche
Phase 3
420
Ankara, Diyarbakır, Edirne, Istanbul, Izmir, Kadiköy, Seyhan, Sihhiye/Ankara
2023-06-07
Recruiting
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
NCT05797168Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer, Lung Squamous Cell Carcinoma
DrugsTorvutatug samrotecan·Palacaparib·Saruparib·Paraplatin
AstraZeneca
Phase 1/2
602
Ankara, Istanbul
2023-06-05
Recruiting
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
NCT05714085Heart Failure, Left Ventricular Systolic Dysfunction
DrugVericiguat
Merck Sharp & Dohme LLC
Phase 2/3
342
Ankara, Istanbul, Izmir
2023-05-31
Active, closed
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
NCT05740566Small Cell Lung Cancer (SCLC)
DrugsAmrubicin·Lurbinectedin·Tarlatamab·Topotecan
Amgen
Phase 3
509
Ankara, Denizli, Istanbul, Izmir, Malatya
2023-05-31
Recruiting
A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
NCT05895786Myositis
Pfizer
Phase 3
318
Ankara
2023-05-20
Active, closed
A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer
NCT05908734Carcinoma, Non-Small-Cell Lung
DrugsCetrelimab·Amivantamab
Janssen Research & Development, LLC
Phase 1/2
71
Adana, Ankara, Istanbul, Izmir, Sakarya
2023-05-18
Recruiting
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
NCT05319730Esophageal Squamous Cell Carcinoma
DrugsMK-4830·Steroid mouthwash (dexamethasone·Acetaminophen·Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Phase 1/2
230
Adana, Ankara, Erzurum, Istanbul, Izmir
2023-05-16
Recruiting
Ultrasonographic Evaluation of Arteries of the Hand in Pediatric Patients
NCT06386718Ulnar and Radial Artery
Ankara University
Observational
184
Ankara
2023-05-15
Active, closed
Ankura™ TAA Stent Graft System Post-Market Clinical Follow-up Study
NCT05639569Aneurysm Thoracic, Dissection of Thoracic Aorta
Lifetech Scientific (Shenzhen) Co., Ltd.
Observational
147
Ankara, Erzurum, Eskişehir, Gaziantep, Izmir
2023-05-03
Recruiting
Ethanol Sclerotherapy Prior to ART
NCT05962775Endometrioma, Infertility, Sclerotherapy, ART
Ankara University
Not applicable
84
Adana, Ankara, Istanbul
2023-05-01
Active, closed
A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)
NCT05557591Advanced Non-Small Cell Lung Cancer
DrugsBNT116·Cemiplimab
Regeneron Pharmaceuticals
Phase 2
51
Adana, Yüreğir, Kadıköy, Bornova, Ankara, Istanbul, Izmir
2023-04-21
Rows per page Showing 1001–1100 of 1457
Previous 9 10 11 12 13 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Turkish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 29 September 2026. https://priyalifescience.com/clinical-trials-turkey/city/ankara?page=11

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Turkey and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,432 studies in total at the last sync on 26 Sep 2026, 19:51 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,457 of those studies with a site in Ankara.

How many clinical trials are recruiting in Ankara?

706 of the 1,457 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:51 UTC sync. A further 176 have not yet opened recruitment, 513 are active but closed to new participants, and 62 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.